Drug intelligence / Profile preview

Tongbi San

Development stage: Unknown
Lead developer: Nanyang Second General Hospital
Administration: Oral

Overview

Tongbi San (also known as Tongbi powder) is a Traditional Chinese Medicine (TCM) herbal formulation developed by Nanyang Second General Hospital for the treatment of acute gouty arthritis, specifically targeting the damp-heat accumulation syndrome. The formula is designed to alleviate clinical symptoms, reduce joint pain, and lower systemic inflammatory markers, including Interleukin-6 (IL-6), as well as serum uric acid levels. In clinical research, it is often evaluated as an adjunctive therapy alongside conventional non-steroidal anti-inflammatory drugs (NSAIDs) like etoricoxib to improve therapeutic outcomes and safety profiles in patients experiencing acute gout flares.

Other names: Tongbi powderTongbi-San

Targets

IL-6 (Interleukin 6)

Beyond the preview

Go deeper on Tongbi San.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tongbi San.

Explore the full profile